Skip to content
mapperlab
← Dashboard
Stock

ZNTL

Zentalis Pharmaceuticals, Inc.
Latest close $3.637 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
8
Current + past
New this quarter
0
Exited this quarter
0

Marquee-fund ownership over time

Aug 7, 2020Aug 9, 2024Nov 14, 2024Feb 17, 2026
Now
7

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies$3.00$3.63+21%
Citadel Advisors$2.89$3.63+25%
Two Sigma Investments$2.89$3.63+25%
D.E. Shaw$2.89$3.63+25%
Millennium Management$2.89$3.63+25%
AQR Capital Management$3.95$3.63-8%
Point72 Asset Management$2.36$3.63+54%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Viking Global Investors→ $23-35%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Zentalis Pharmaceuticals, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
1
Filings · last 90d
1
Total on file
217
Recent SEC buffer
Most recent
May 27, 2026

30d / 90d windows measured from May 27, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 217 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Zentalis Pharmaceuticals, Inc.

Annual figures sourced directly from Zentalis Pharmaceuticals, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$0
FY2025-100% YoY
Net income
-$137.06M
FY2025+17% YoY
EPS (diluted)
$-1.91
FY2025+18% YoY
Free cash flow(?)
-$125.25M
FY2025+27% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Zentalis Pharmaceuticals, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Point72 Asset ManagementQ1 2026open$2.36$3.63+54%
AQR Capital ManagementQ4 2024open$3.95$3.63-8%
Citadel AdvisorsQ3 2024open$2.89$3.63+25%
Two Sigma InvestmentsQ3 2024open$2.89$3.63+25%
D.E. ShawQ3 2024open$2.89$3.63+25%
Millennium ManagementQ3 2024open$2.89$3.63+25%
Renaissance TechnologiesQ3 2024open$3.00$3.63+21%
Viking Global InvestorsQ3 2020Q4 2022$35$23-35%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.